Vyjuvek (beremagene geperpavec) topical gene therapy for dystrophic epidermolysis bullosa
This policy governs prior authorization and coverage criteria for Vyjuvek (beremagene geperpavec) for treatment of open wounds in patients with dystrophic epidermolysis bullosa (DEB) for Mass General Brigham Health Plan members, including Commercial, MassHealth, and Medicare Advantage variations.
Summary of evidence added and references updated.
Coverage Criteria
Initial Therapy / Authorization Criteria
Covered when ALL of the following are met:
Vyjuvek is applied weekly to open wounds until wounds are closed.
Although the U.S. Food and Drug Administration has authorized Vyjuvek (beremagene geperpavec, B‑VEC) for dystrophic epidermolysis bullosa, the policy explicitly notes that clinical evidence for use in dominant DEB is minimal. The pivotal datasets and subsequent literature primarily support treatment of recessive DEB; only a single patient with dominant DEB was enrolled across the pivotal studies. Because evidence for dominant DEB is limited, requests for B‑VEC in dominant DEB should be evaluated against the policy’s standard authorization criteria, and payers may apply additional scrutiny or require documentation supporting clinical rationale when dominant DEB is the only listed diagnosis.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.